Home › Funds › ARMISTICE CAPITAL, LLC › GSK

ARMISTICE CAPITAL, LLC position in GSK

GSK PLC · Health Care

ARMISTICE CAPITAL, LLC reported holding 724,000 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$34.9M, representing 0.48% of its reported portfolio and ranking #23 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed GSK holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)724.00K sh
Reported value held$34.88M
Portfolio Weight0.48%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's GSK position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in GSK in Q3 2023 at 285,000 shares (US$10.3M). The position peaked in Q4 2023 at 2,196,000 shares, worth US$81.4M. Across 11 filings, ARMISTICE CAPITAL, LLC increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 724,000 shares valued at US$34.9M — an increase of 424,000 shares quarter over quarter.. Notable position changes include a 671% increase in Q4 2023 (shares rose 16% over the following quarter), a 354% increase in Q4 2024 (shares rose 15% over the following quarter), a 141% increase in Q3 2026 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 285.00K $10.33M New
Q4 2023 2.20M $81.38M Add
Q1 2024 964.00K $41.33M Reduce
Q2 2024 1.50M $57.75M Add
Q3 2024 524.00K $21.42M Reduce
Q4 2024 2.38M $80.42M Add
Q1 2025 378.00K $14.64M Reduce
Q4 2025 1.00M $49.04M New
Q1 2026 236.00K $13.02M Reduce
Q2 2026 300.00K $15.73M Add
Q3 2026 724.00K $34.88M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GSK and 13F data

GSK (GSK PLC) is a Health Care company. 19 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.08B), PRIMECAP MANAGEMENT CO/CA/ (US$1.21B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GSK

All GSK fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held GSK?

ARMISTICE CAPITAL, LLC has disclosed GSK holdings in 11 of the last 13 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in GSK?

As of Q3 2026, ARMISTICE CAPITAL, LLC holds 724.00K shares of GSK (GSK PLC), valued at $34.88M, representing 0.48% of its reported portfolio and ranking #23.

Has ARMISTICE CAPITAL, LLC been buying or selling GSK?

In the latest 13F filing (Q3 2026), ARMISTICE CAPITAL, LLC increased its position in GSK. The position peaked in Q4 2023 at 2.20M shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 19 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.